Pedro Herranz

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

Medicine, Dermatology, Immunology +17

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al. · British Journal of Dermatology · 2020 · 595 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting

Eva Vilarrasa, Pedro Herranz, L. Puig et al. · British Journal of Dermatology · 2012 · 99 citations

Medicine, Dermatology, Pharmacotherapy +14

Postmenopausal frontal fibrosing alopecia

Elena Naz, Carmen Vidaurrázaga, Natalia Hernández‐Cano et al. · Clinical and Experimental Dermatology · 2003 · 93 citations

Medicine, Dermatology, Pathology +13

Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population

Elena Ramı́rez, Teresa Bellón, Hoi Y. Tong et al. · Pharmacological Research · 2016 · 80 citations

Life Sciences, Immunology, Neurology +11